BIOGEN INC. (BIIB)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$3,382.7M
Cash & Equivalents
$645.5M
Quarterly Burn Rate
$29,080M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
DACLIZUMAB
ZINBRYTA |
APPROVED | ADPKD, Advanced Solid Tumors, ALS, Alzheimer Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Autosomal Dominant Polycystic Kidney, Bipolar Disorder I, Bipolar Disorder II, Breast Cancer, Choroideremia, Chronic Lymphocytic Leukemia, CKD Associated With Type 1 Diabetes, Clinically Isolated Syndrome, Cognitive Impairment Associated With Schizophrenia (CIAS), Colitis, Ulcerative, Crohn's Disease, Diabetes Mellitus, Type 2, Drug Interactions, Eye Diseases, Fatigue, Focal Segmental Glomerulosclerosis, Frontotemporal Dementia, Healthy, Healthy Adult Subjects, Healthy Volunteer, Healthy Volunteers, Hearing Loss, Sensorineural, Hypervolemic Hyponatremia, Hyponatremia With Normal Extracellular Fluid Volume, IgA Nephropathy, Kidney Insufficiency, Kidney Transplantation, Lupus Erythematosus, Systemic, Major Depressive Episode, Metastatic or Incurable Non-small Cell Lung Cancer, Microvascular Inflammation, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting |
|
INTERFERON BETA-1A
AVONEX |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.